About Kinnate Biopharma
Kinnate Biopharma Inc. is a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. The Company utilizes its deep specialization in structure-based drug discovery, translational research and patient-driven precision medicine, which is collectively referred as Kinnate Discovery Engine, to develop its targeted therapies. The Company's advanced product candidate is KIN-2787, which is a rapidly accelerated fibrosarcoma (RAF) inhibitor, which is being developed for the treatment of patients with lung cancer, melanoma and other solid tumors. The Company's other product candidate include KIN-3248 and KIN004.